case_images: PMC6637684_01
case_images: Cutaneous lesions located in left costal dermatome, characterized by multiple necrotic lesions.
case_images: CRII2019-6357256.001.jpg
case_images: PMC6637684_01_CRII2019-6357256.001.jpg
case_images: fig1
case_images: The patient received twelve doses of efalizumab, but the drug was suspended due to herpes zoster dermatitis (Figure 1), and treatment with acyclovir was indicated with adequate clinical response.
case_images: Comparison between CRP levels during application of omalizumab. The variation of protein levels does not correlate with the clinical manifestations of the patient and IgE levels.
case_images: CRII2019-6357256.002.jpg
case_images: PMC6637684_01_CRII2019-6357256.002.jpg
case_images: fig2
case_images: The variations of CRP (C-reactive protein) do not correlate with the clinical manifestations of the patient and IgE levels (Figures 2 and 3).
case_images: Comparison between IgE levels during application of omalizumab. The y-axis: serum IgE expressed in IU/ml; the x-axis: the dates on which these levels were taken. The decrease in IgE levels was clearly observed during the application of omalizumab; these increased after treatment was discontinued.
case_images: CRII2019-6357256.003.jpg
case_images: PMC6637684_01_CRII2019-6357256.003.jpg
case_images: fig3
case_images: The variations of CRP (C-reactive protein) do not correlate with the clinical manifestations of the patient and IgE levels (Figures 2 and 3).